Furthermore, results obtained for the expression of Slan (6-sulfo LacNAc), reported as a marker differentiating new subsets of CD16+ monocytes that are expanded in patients with sarcoidosis (Slan-negative, CD16+) or depleted in hereditary diffuse leukodystrophy (Slan-positive, CD16+)33, showed that although the tendency is similar in both blood and peritoneal subsets, the overall percentages of Slan expressing cells were statistically higher in the latter compartment. Here, SECISBP2L is linked to sarcoidosis.